US Stock MarketDetailed Quotes

AZN AstraZeneca

Watchlist
  • 66.400
  • +0.770+1.17%
Close Nov 25 16:00 ET
  • 66.160
  • -0.240-0.36%
Post 20:01 ET
205.88BMarket Cap32.00P/E (TTM)

AstraZeneca Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
18.04%13.57B
13.33%12.94B
16.55%12.68B
3.29%45.81B
7.29%12.02B
4.64%11.49B
5.99%11.42B
-4.49%10.88B
18.53%44.35B
-6.69%11.21B
Operating revenue
18.04%13.57B
13.33%12.94B
16.55%12.68B
3.29%45.81B
7.29%12.02B
4.64%11.49B
5.99%11.42B
-4.49%10.88B
18.53%44.35B
-6.69%11.21B
Cost of revenue
47.06%3.08B
11.38%2.18B
16.43%2.22B
-33.27%8.27B
-20.41%2.31B
-29.75%2.1B
-34.62%1.96B
-45.74%1.91B
-0.37%12.39B
-37.30%2.9B
Gross profit
11.57%10.48B
13.74%10.76B
16.57%10.46B
17.47%37.54B
16.96%9.72B
17.46%9.4B
21.65%9.46B
13.90%8.97B
27.94%31.96B
12.47%8.31B
Operating expense
12.56%8.38B
14.41%8.01B
10.20%7.35B
5.00%28.82B
8.25%6.93B
10.19%7.44B
-3.23%7B
-4.79%6.67B
9.27%27.45B
-27.90%6.4B
Selling and administrative expenses
7.28%5.29B
-1.09%5.06B
10.42%4.63B
1.32%18.22B
4.65%3.98B
11.95%4.93B
6.38%5.12B
-15.55%4.19B
15.36%17.98B
-26.11%3.81B
-Selling and marketing expense
12.40%145M
0.76%132M
0.75%135M
1.32%18.22B
1.27%17.83B
2.38%129M
1.55%131M
7.20%134M
15.36%17.98B
15.30%17.6B
-General and administrative expense
7.15%5.14B
-1.14%4.93B
10.74%4.5B
----
----
12.23%4.8B
6.52%4.99B
-16.14%4.06B
----
----
Research and development costs
20.55%3.12B
12.79%3.01B
6.59%2.78B
12.02%10.94B
17.07%3.07B
5.13%2.58B
4.75%2.67B
22.41%2.61B
0.27%9.76B
1.59%2.63B
Other operating expenses
----
----
----
-18.00%164M
----
----
----
----
-35.06%200M
----
Operating profit
7.78%2.11B
11.81%2.75B
34.97%3.12B
93.31%8.72B
46.13%2.79B
56.95%1.95B
355.66%2.46B
162.87%2.31B
3,346.04%4.51B
228.45%1.91B
Net non-operating interest income expense
5.84%-274M
6.54%-343M
-5.23%-302M
-3.12%-1.29B
-9.58%-343M
10.19%-291M
-25.26%-367M
10.03%-287M
-1.30%-1.25B
-0.64%-313M
Non-operating interest income
81.19%183M
56.25%100M
42.31%111M
271.60%301M
109.68%65M
573.33%101M
255.56%64M
358.82%78M
88.37%81M
3,000.00%31M
Non-operating interest expense
16.58%457M
2.78%443M
13.15%413M
19.47%1.59B
18.60%408M
15.63%392M
38.59%431M
8.63%365M
4.23%1.33B
10.26%344M
Other net income (expense)
Special income (charges)
----
----
--0
29.93%-529M
-90.81%-1.56B
----
----
--241M
-163.18%-755M
---816M
-Less：Restructuring and merger&acquisition
----
----
----
185.71%520M
----
----
----
----
333.33%182M
----
-Less:Other special charges
----
----
----
-98.43%9M
63.56%1.04B
----
----
---241M
146.32%573M
--634M
Income before tax
10.65%1.83B
14.80%2.4B
23.78%2.8B
175.85%6.9B
15.30%897M
79.18%1.65B
745.34%2.09B
309.04%2.26B
1,043.77%2.5B
222.33%778M
Income tax
44.16%395M
75.00%469M
35.37%620M
218.43%938M
50.00%-62M
138.06%274M
337.17%268M
177.58%458M
-108.42%-792M
57.24%-124M
Net income
3.99%1.43B
5.93%1.93B
20.84%2.18B
81.02%5.96B
6.32%959M
-16.08%1.38B
405.56%1.82B
364.95%1.8B
2,763.48%3.29B
360.69%902M
Net income continuous Operations
3.99%1.43B
5.93%1.93B
20.84%2.18B
81.02%5.96B
6.32%959M
-16.08%1.38B
405.56%1.82B
364.95%1.8B
2,763.48%3.29B
360.69%902M
Minority interest income
0.00%4M
-50.00%1M
0.00%1M
20.00%6M
-200.00%-1M
100.00%4M
2M
-50.00%1M
66.67%5M
0.00%1M
Net income attributable to the parent company
4.00%1.43B
6.00%1.93B
20.85%2.18B
81.11%5.96B
6.55%960M
-16.22%1.37B
405.00%1.82B
367.10%1.8B
2,835.71%3.29B
359.65%901M
Preferred stock dividends
Other preferred stock dividends
0
0
0
0
0
0
0
0
0
0
Net income attributable to common stockholders
4.00%1.43B
6.00%1.93B
20.85%2.18B
81.11%5.96B
6.55%960M
-16.22%1.37B
405.00%1.82B
367.10%1.8B
2,835.71%3.29B
359.65%901M
Basic earnings per share
3.37%0.46
5.98%0.62
21.55%0.705
81.13%1.92
6.90%0.31
-16.04%0.445
408.70%0.585
364.00%0.58
2,550.00%1.06
363.64%0.29
Diluted earnings per share
3.41%0.455
5.98%0.62
20.69%0.7
80.57%1.905
6.90%0.31
-16.19%0.44
408.70%0.585
364.00%0.58
2,537.50%1.055
363.64%0.29
Dividend per share
7.53%0.5
0
0.00%0.985
0.00%1.45
0
0.00%0.465
0
0.00%0.985
3.57%1.45
0
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
NonUS-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
--
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 18.04%13.57B13.33%12.94B16.55%12.68B3.29%45.81B7.29%12.02B4.64%11.49B5.99%11.42B-4.49%10.88B18.53%44.35B-6.69%11.21B
Operating revenue 18.04%13.57B13.33%12.94B16.55%12.68B3.29%45.81B7.29%12.02B4.64%11.49B5.99%11.42B-4.49%10.88B18.53%44.35B-6.69%11.21B
Cost of revenue 47.06%3.08B11.38%2.18B16.43%2.22B-33.27%8.27B-20.41%2.31B-29.75%2.1B-34.62%1.96B-45.74%1.91B-0.37%12.39B-37.30%2.9B
Gross profit 11.57%10.48B13.74%10.76B16.57%10.46B17.47%37.54B16.96%9.72B17.46%9.4B21.65%9.46B13.90%8.97B27.94%31.96B12.47%8.31B
Operating expense 12.56%8.38B14.41%8.01B10.20%7.35B5.00%28.82B8.25%6.93B10.19%7.44B-3.23%7B-4.79%6.67B9.27%27.45B-27.90%6.4B
Selling and administrative expenses 7.28%5.29B-1.09%5.06B10.42%4.63B1.32%18.22B4.65%3.98B11.95%4.93B6.38%5.12B-15.55%4.19B15.36%17.98B-26.11%3.81B
-Selling and marketing expense 12.40%145M0.76%132M0.75%135M1.32%18.22B1.27%17.83B2.38%129M1.55%131M7.20%134M15.36%17.98B15.30%17.6B
-General and administrative expense 7.15%5.14B-1.14%4.93B10.74%4.5B--------12.23%4.8B6.52%4.99B-16.14%4.06B--------
Research and development costs 20.55%3.12B12.79%3.01B6.59%2.78B12.02%10.94B17.07%3.07B5.13%2.58B4.75%2.67B22.41%2.61B0.27%9.76B1.59%2.63B
Other operating expenses -------------18.00%164M-----------------35.06%200M----
Operating profit 7.78%2.11B11.81%2.75B34.97%3.12B93.31%8.72B46.13%2.79B56.95%1.95B355.66%2.46B162.87%2.31B3,346.04%4.51B228.45%1.91B
Net non-operating interest income expense 5.84%-274M6.54%-343M-5.23%-302M-3.12%-1.29B-9.58%-343M10.19%-291M-25.26%-367M10.03%-287M-1.30%-1.25B-0.64%-313M
Non-operating interest income 81.19%183M56.25%100M42.31%111M271.60%301M109.68%65M573.33%101M255.56%64M358.82%78M88.37%81M3,000.00%31M
Non-operating interest expense 16.58%457M2.78%443M13.15%413M19.47%1.59B18.60%408M15.63%392M38.59%431M8.63%365M4.23%1.33B10.26%344M
Other net income (expense)
Special income (charges) ----------029.93%-529M-90.81%-1.56B----------241M-163.18%-755M---816M
-Less：Restructuring and merger&acquisition ------------185.71%520M----------------333.33%182M----
-Less:Other special charges -------------98.43%9M63.56%1.04B-----------241M146.32%573M--634M
Income before tax 10.65%1.83B14.80%2.4B23.78%2.8B175.85%6.9B15.30%897M79.18%1.65B745.34%2.09B309.04%2.26B1,043.77%2.5B222.33%778M
Income tax 44.16%395M75.00%469M35.37%620M218.43%938M50.00%-62M138.06%274M337.17%268M177.58%458M-108.42%-792M57.24%-124M
Net income 3.99%1.43B5.93%1.93B20.84%2.18B81.02%5.96B6.32%959M-16.08%1.38B405.56%1.82B364.95%1.8B2,763.48%3.29B360.69%902M
Net income continuous Operations 3.99%1.43B5.93%1.93B20.84%2.18B81.02%5.96B6.32%959M-16.08%1.38B405.56%1.82B364.95%1.8B2,763.48%3.29B360.69%902M
Minority interest income 0.00%4M-50.00%1M0.00%1M20.00%6M-200.00%-1M100.00%4M2M-50.00%1M66.67%5M0.00%1M
Net income attributable to the parent company 4.00%1.43B6.00%1.93B20.85%2.18B81.11%5.96B6.55%960M-16.22%1.37B405.00%1.82B367.10%1.8B2,835.71%3.29B359.65%901M
Preferred stock dividends
Other preferred stock dividends 0000000000
Net income attributable to common stockholders 4.00%1.43B6.00%1.93B20.85%2.18B81.11%5.96B6.55%960M-16.22%1.37B405.00%1.82B367.10%1.8B2,835.71%3.29B359.65%901M
Basic earnings per share 3.37%0.465.98%0.6221.55%0.70581.13%1.926.90%0.31-16.04%0.445408.70%0.585364.00%0.582,550.00%1.06363.64%0.29
Diluted earnings per share 3.41%0.4555.98%0.6220.69%0.780.57%1.9056.90%0.31-16.19%0.44408.70%0.585364.00%0.582,537.50%1.055363.64%0.29
Dividend per share 7.53%0.500.00%0.9850.00%1.4500.00%0.46500.00%0.9853.57%1.450
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards NonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAPNonUS-GAAP
Audit Opinions ------Unqualified Opinion------------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme Infectious Disease
Infectious Disease
Intraday+0.89%